Jun 18, 2024

Featuring perspectives from Dr Petros Grivas, including the following topics:

• Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00)
• Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16)
• Perspective on recurrence mechanisms of NMIBC (22:21)
• Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27)
• Importance of collaborative care for patients with bladder cancer (42:02)
• Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57)
• Monitoring and management of T-DXd-associated side effects (1:00:47)
• Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32)
• Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22)
• Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer’s disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12)

CME information and select publications